title: Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
abstract: The advanced understanding of the molecular biology and immunology of chronic myeloid leukemia (CML) has led to novel therapeutic strategies unique to this disease. CML responds to immune-mediated therapies, including stem cell transplantation, donor lymphocyte infusion (DLI), and interferon alfa. T cells and other immune effectors are implicated in the mechanisms of action of these immune therapies. Recently, clinical observations supported by laboratory data have demonstrated the presence of CML-specific T cells in patients. Several proteins may potentially act as leukemia-specific antigens for major histocompatibility complex (MHC)-restricted cytotoxicity in CML, and active specific therapies (vaccines) are in development. Antigens under investigation include bcr-abl, PR1, Wilms tumor protein (WT1), minor histocompatibility antigens (mH), CML-66, CML-28, and survivin. Other strategies target vascular endothelial growth factor (VEGF) and heat shock protein 90 (Hsp90) inhibitors or make use of CML-derived dendritic cells (DC).
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Schwartz
authors.forename: Javier
authors.initials: J
authors.lastname: Pinilla-Ibarz
authors.forename: Rui Rong
authors.initials: RR
authors.lastname: Yuan
authors.forename: David A
authors.initials: DA
authors.lastname: Scheinberg
mesh_terms: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents